ProblemUS neurology teams lose days or weeks after an MS therapy decision because prior auth, site-of-care redirects, new ICD-10 subtype codes, copay forms, and infusion orders still get rebuilt by hand across payer portals, spreadsheets, and phone calls.
SolutionNeuroReady MS gives infusion coordinators a narrow exception queue that flags the exact blocker on each Ocrevus, Tysabri, Briumvi, or Lemtrada start, drafts the next document request, and tracks when a patient is genuinely schedulable.
Market opportunityAlmost 1 million Americans live with MS, the MS drugs market was about $22.96B in 2025, and infusion admin budgets already exist around WeInfuse, WellSky, and Ruma Care, leaving room for a $499-$1,500/month last-mile workflow layer.